Express Scripts (ESRX) Tops Q2 EPS by 1c

Express Scripts (NASDAQ: ESRX) reported Q2 EPS of $2.22, $0.01 better than the analyst estimate of $2.21. Revenue for the quarter came in at $25.64 billion versus the consensus estimate of $25.4 billion.

2018 Guidance

The Company increased its core business 2018 adjusted EBITDA guidance from a range of $5,250 million to $5,400 million to a range of $5,275 million to $5,425 million, which represents growth of 8% over core business 2017 adjusted EBITDA at the midpoint of the range. All previously provided consolidated guidance remains unchanged. All consolidated and core guidance, including expectations around enterprise value initiatives, reflects Express Scripts as an independent company and does not incorporate any impacts of a 2018 closing of the Cigna transaction.

For earnings history and earnings-related data on Express Scripts (ESRX) click here.

You May Also Be Interested In